肾移植后骨骼和矿物质代谢紊乱：治疗策略。
Bone and mineral disorders after kidney transplantation: therapeutic strategies.
机构信息
Division of Nephrology and Hypertension, University of California Irvine Medical Center, Orange, CA, USA; Department of Medicine, Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Department of Medicine, Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
出版信息
Transplant Rev (Orlando). 2014 Apr;28(2):56-62. doi: 10.1016/j.trre.2013.12.003. Epub 2013 Dec 12.
Mineral and bone diseases (MBD) are common in patients with chronic kidney disease who undergo kidney transplantation. The incidence, types and severity of MBD vary according to the duration of chronic kidney disease, presence of comorbid conditions and intake of certain medications. Moreover, multiple types of pathology may be responsible for MBD. After successful reversal of uremia by kidney transplantation, many bone and mineral disorders improve, while immunosuppression, other medications, and new and existing comorbidities may result in new or worsening MBD. Chronic kidney disease is also common after kidney transplantation and may impact bone and mineral disease. In this article, we reviewed the prevalence, pathophysiology, and impact of MBD on post-transplant outcomes. We also discussed the diagnostic approach; immunosuppression management and potential treatment of MBD in kidney transplant recipients.
矿物质和骨代谢疾病（MBD）在接受肾移植的慢性肾脏病患者中很常见。MBD 的发生率、类型和严重程度取决于慢性肾脏病的持续时间、合并症的存在以及某些药物的摄入。此外，多种类型的病理可能导致 MBD。肾移植成功逆转尿毒症后，许多骨骼和矿物质紊乱得到改善，而免疫抑制、其他药物以及新的和现有的合并症可能导致新的或加重的 MBD。慢性肾脏病在肾移植后也很常见，可能会影响骨骼和矿物质疾病。在本文中，我们回顾了 MBD 的患病率、病理生理学以及对移植后结局的影响。我们还讨论了 MBD 的诊断方法、免疫抑制管理以及肾移植受者的潜在治疗方法。
Zotero 插件